Japan Dermatological Therapeutics Market Report 2022 to 2030

Japan Dermatological Therapeutics Market Analysis

$ 3999

Japan Dermatological Therapeutics Market is at around $2.56 Bn in 2023 and is projected to reach $4.71 Bn in 2030, exhibiting a CAGR of 9.1% during the forecast period. The market is being driven by an increasing aging population, a growing prevalence of dermatological disorders, and technological advancements in treatment options. The market is dominated by key players like Takeda Pharmaceutical Company Limited (JPN), Shionogi & Co., Ltd. (JPN), Eisai Co., ltd. (JPN), Almirall SA, Pfizer Inc., AbbVie Inc., Amgen Inc., Novartis AG, Johnson & Johnson, and GlaxoSmithKline Plc.

ID: IN10JPPH035 CATEGORY: Pharmaceuticals GEOGRAPHY: Japan AUTHOR: Aneri Parekh

Buy Now

Japan Dermatological Therapeutics Market Executive Summary

Japan Dermatological Therapeutics Market is at around $2.56 Bn in 2023 and is projected to reach $4.71 Bn in 2030, exhibiting a CAGR of 9.1% during the forecast period.

The field of dermatological therapeutics deals with the diagnosis, treatment, and management of skin diseases and disorders. The goal of this field is to create efficient therapeutic interventions to treat a variety of dermatological conditions, such as psoriasis, acne, eczema, and skin infections. These interventions may include topical treatments, pharmaceuticals, and procedural methods. The objective is to employ evidence-based therapy strategies to increase overall well-being, reduce symptoms, and improve skin health.

Growing aging populations and a rise in dermatological problems are driving the continuous growth of the Japanese dermatological therapeutics market. The market is growing owing to new treatments and technological advancements, with an emphasis on tailored and focused therapies. To introduce novel dermatological medicines, major businesses are spending on research and development.

In 2023, dermatological treatments generated $40.94 Bn in revenue worldwide. This enormous rise, a sign of a modernizing civilization, is made possible by highly productive industrial processes and cutting-edge technologies. A few of the elements fueling the industry's impressive rise include increasing investment, continuous innovation, and enhanced accessibility.

Takeda holds a substantial market position in the Japanese dermatology treatments market due to its well-established portfolio and robust local presence. The company specializes in cutting-edge treatments for a range of skin ailments, such as acne, psoriasis, and atopic dermatitis. Takeda uses its extensive global research and development network to introduce state-of-the-art dermatology products to the Japanese market. Shionogi & Co., Ltd., and AbbVie are among the company's domestic and international competitors respectively.

Japan dermatological therapeutics market

Market Dynamics

Market Growth Drivers:

Growing Prevalence of Dermatological Disorders: The need for dermatological therapies is driven by an increase in the incidence of dermatological disorders such as psoriasis, acne, atopic dermatitis, and skin cancer.

Technological Developments in Treatment Options: The creation of novel and efficient treatment alternatives as well as improvements in dermatological device technology, is propelling the market.

Growing Aging Population: As people get older, there's generally a rise in the prevalence of aging-related dermatological disorders, which is driving up the need for treatment measures.

Market Restraints:

Regulatory Obstacles: The market's expansion may be impeded by strict laws and drawn-out approval procedures for new dermatological goods. Pharmaceutical companies may have to invest a lot of time and resources to comply with regulatory regulations.

Cultural Factors: Aspects related to culture may influence the adoption and acceptance of specific dermatological treatments. Growth in the market may be impacted by preferences for complementary or alternative medicine over Western medications.

Generic Competition: As dermatological medicine patents expire, generic copies of these medications may become more prevalent, which could result in lower prices and lower profit margins for pharmaceutical corporations.

Healthcare Policies and Regulatory Landscape

The regulatory body that works with the Ministry of Health, Labour, and Welfare in Japan is called the Pharmaceuticals and Medical Devices Agency (PMDA). Sending the required funds and the NDA dossier to the PMDA is required. The PMDA may request more information after examining the NDA dossier. If the PMDA is satisfied with the NDA dossier, they will approve the drug for sale. Japan has an extremely stringent and comprehensive drug approval procedure. It is necessary to submit a New Drug Application (NDA), which is reviewed in-depth. By ensuring that only drugs that meet the highest quality standards are permitted to be supplied, the complexity of drug control in Japan increases.

Competitive Landscape

Key Players:

Takeda Pharmaceutical Company Limited (JPN)
Shionogi & Co., Ltd. (JPN)
Eisai Co., ltd. (JPN)
Almirall SA
Pfizer Inc.
AbbVie Inc.
Amgen Inc.
Novartis AG
Johnson & Johnson
GlaxoSmithKline Plc.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Japan Dermatological Therapeutics Market Segmentation

By Type

Prescription-based Drugs
Over-the-counter Drugs

By Disease

Alopecia
Herpes
Psoriasis
Rosacea
Skin Cancer
Acne
Atopic Dermatitis
Vitiligo
Hidradenitis
Other Applications

By Drug Class

Anti-infectives
Corticosteroids
Anti-acne
Calcineurin Inhibitors
Retinoids
Other Drug Classes

By Route of Administration

Topical Administration
Oral Administration
Parenteral Administration

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.